Laurent Pharmaceuticals Inc.

18 articles about Laurent Pharmaceuticals Inc.

• Laurent Pharmaceuticals Receives Health Canada’s Approval to Initiate Phase 2/3 Clinical Trial in Long COVID

  8/29/2023

  Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company, today announced that it has obtained the approval from Health Canada to initiate ESSOR, an adaptive Phase 2/3 randomized placebo-controlled trial testing its oral drug candidate LAU-7b as a potential treatment for Long COVID.

• Laurent Pharmaceuticals Presents Results from Phase 2 Clinical Study of LAU-7b in Cystic Fibrosis at the NACFC 2022

  11/3/2022

  Laurent Pharmaceuticals Inc. (the “Company”), a clinical-stage biopharmaceutical company developing LAU-7b (oral fenretinide) as a first-in-class inflammation-controlling drug candidate for Cystic Fibrosis (CF), announces the presentation of results from its placebo-controlled Phase 2 APPLAUD 24-week clinical study in adults with CF at the North American Cystic Fibrosis Conference (NACFC) currently held in Philadelphia, United States.

• Laurent Pharmaceuticals Starts Phase 3 Study With Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients

  2/15/2022

  Laurent Pharmaceuticals Inc. today announced that Luminis Health Research Institute in Annapolis MD, USA, has dosed the first patient in the Phase 3 expansion of the RESOLUTION Phase 2/3 clinical trial evaluating the efficacy of the novel COVID-19 oral antiviral LAU-7b.

• Laurent Pharmaceuticals Extends COVID-19 Phase 2 Study with Oral Antiviral LAU-7b that has Showed 100% Reduction in the Risk of Progression onto Mechanical Ventilation and Death

  12/15/2021

  FDA allows Phase 2 study extension focusing on moderate-to-severe COVID-19 patients and grants Type B meeting to discuss eligibility to Emergency Use Authorization (EUA) and Phase 3 clinical development.

• Laurent Pharmaceuticals Announces Topline Results from its Phase 2 RESOLUTION Clinical Trial of LAU-7b for the Treatment of COVID-19

  9/30/2021

  Laurent Pharmaceuticals Inc. reported today topline results from its Phase 2 RESOLUTION clinical trial in hospitalized COVID-19 patients.

• Laurent Pharmaceuticals Completes Patients Enrollment in Phase 2 Study of LAU-7b for the Treatment of COVID-19

  5/20/2021

  Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing the first-in-class pro-resolving drug LAU-7b, today announces that it has completed the enrollment for its placebo-controlled Phase 2 RESOLUTION clinical study of hospitalized patients with COVID-19. The study, which enrolled 240 patients across Canada and United States, is expected to report top-line results in Q3 2021.

• Laurent Pharmaceuticals Provides Clinical Development Update

  4/8/2021

  Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing first-in-class pro-resolving drug LAU-7b, today announces that the independent Data Safety Monitoring Board (DSMB) for the Phase 2 RESOLUTION study in hospitalized patients with COVID-19

• Laurent Pharmaceuticals Receives Approval from FDA to Initiate its COVID-19 Phase 2 Clinical Trial in the United States

  8/27/2020

  The Phase 2 study aims to evaluate the dual antiviral and inflammation-controlling effects of the company's LAU-7b oral drug candidate against COVID-19 infection

• Laurent Pharmaceuticals Receives Health Canada’s Approval to Initiate COVID-19 Clinical Trial

  5/6/2020

  Company to test LAU-7b’s dual pro-resolving inflammation and antiviral properties against COVID-19

• 

  Biopharma Update on the Novel Coronavirus: May 6

  5/6/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
• 

  Clinical Catch-Up: April 6-10

  4/13/2020

  It was a very busy week for clinical trial news. Here’s a look.

• Laurent Pharmaceuticals Joins Battle Against COVID-19

  4/9/2020

  Laurent Pharmaceuticals to initiate world-first testing of LAU-7b in COVID-19 patients

• Laurent Pharmaceuticals Receives a CAD 2.7M Financing from BioMed Propulsion Fund

  12/4/2019

  LAU-7b is an oral drug acting on the resolution phase of the inflammation, with the potential to treat chronic pulmonary inflammation that leads to irreversible lung damage in patients with CF.

• Laurent Pharmaceuticals Receives an Additional up to $3M Award from Cystic Fibrosis Foundation

  10/31/2019

  This adds to the US$ 5 million development award already made available by the Foundation.

• Laurent Pharmaceuticals Welcomes New Investors and Announces Scientific Breakthrough with LAU-7b in Cystic Fibrosis

  10/25/2018

  Laurent Pharmaceuticals Inc. today announced new financing led by Keiretsu Forum Mid-Atlantic, Anges Quebec and Anges Quebec Capital, with participation from existing investors RSJ Gradus, Aligo Innovation, and Cystic Fibrosis Canada. Members from other Keiretsu Forum chapters also invested, as well as a select group of new and existing private individuals.

• Laurent Receives FDA And Health Canada Clearance To Initiate APPLAUD Phase II Clinical Study Of LAU-7b For The Treatment Of Cystic Fibrosis

  4/19/2017

• Laurent Receives $3 Million Development Award From Cystic Fibrosis Foundation Therapeutics, Inc.

  7/26/2016

• Laurent To Receive Investment From Cystic Fibrosis Canada

  3/17/2016